Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $67.61 --0%
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 7 | New: 9
Rating Summary:
12 Buy, 22 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 7 | New: 9
Join SI Premium – FREE
Morgan Stanley analyst David Risinger downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Overweight to Equalweight with a price target of $62.00 (from $70.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $62.89 yesterday.
You May Also Be Interested In
- Citi cuts TJX Companies rating to Neutral, lowers price target
- JPMorgan Upgrades Michelin (ML:FP) (MGDDY) to Overweight
- Citi cuts Lowe's price target to $260, keeps Buy rating
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
